Evaxion A/S (EVAX)

NASDAQ: EVAX · Real-Time Price · USD
2.300
-0.330 (-12.55%)
May 29, 2025, 4:00 PM - Market closed
-12.55%
Market Cap 14.53M
Revenue (ttm) 3.29M
Net Income (ttm) -13.34M
Shares Out 6.32M
EPS (ttm) -6.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 168,291
Open 2.630
Previous Close 2.630
Day's Range 2.171 - 2.640
52-Week Range 1.200 - 20.000
Beta -0.23
Analysts Strong Buy
Price Target 10.00 (+334.78%)
Earnings Date May 27, 2025

About EVAX

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vacci... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 46
Stock Exchange NASDAQ
Ticker Symbol EVAX
Full Company Profile

Financial Performance

In 2024, Evaxion's revenue was $3.34 million, an increase of 4480.82% compared to the previous year's $73,000. Losses were -$10.57 million, -52.24% less than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 334.78% from the latest price.

Price Target
$10.0
(334.78% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conferen...

2 days ago - Seeking Alpha

Evaxion announces business update and first quarter 2025 financial results

COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and an...

2 days ago - GlobeNewsWire

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily ...

3 days ago - Seeking Alpha

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update ...

6 days ago - GlobeNewsWire

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has dosed the first patient in ...

7 days ago - GlobeNewsWire

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

COPENHAGEN, Denmark, April 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data un...

4 weeks ago - GlobeNewsWire

Evaxion to present at World Vaccine Congress

COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two present...

7 weeks ago - GlobeNewsWire

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rønø - Chief Scientific Officer Thomas S...

2 months ago - Seeking Alpha

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a busine...

2 months ago - GlobeNewsWire

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

COPENHAGEN, Denmark, March 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present new data...

2 months ago - GlobeNewsWire

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

COPENHAGEN, Denmark, February 25, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will further enhan...

3 months ago - GlobeNewsWire

Evaxion announces closing of $10.8 million public offering

COPENHAGEN, Denmark, January 31, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...

4 months ago - GlobeNewsWire

Evaxion announces pricing of $10.8 million public offering

COPENHAGEN, Denmark, January 30, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the...

4 months ago - GlobeNewsWire

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

COPENHAGEN, Denmark, January 28, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has received notice...

4 months ago - GlobeNewsWire

Evaxion announces completion of ADS ratio change

COPENHAGEN, Denmark, January 14, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, to...

4 months ago - GlobeNewsWire

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced tha...

4 months ago - GlobeNewsWire

Evaxion announces plan to implement ADS ratio change

COPENHAGEN, Denmark, December 30, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced th...

5 months ago - GlobeNewsWire

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

COPENHAGEN, Denmark, November 12, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new posi...

7 months ago - GlobeNewsWire

Evaxion announces business update and third quarter 2024 financial results

COPENHAGEN, Denmark, October 31, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business u...

7 months ago - GlobeNewsWire

Evaxion to announce business update and third quarter 2024 financial results on October 31

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a busi...

7 months ago - GlobeNewsWire

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence fro...

8 months ago - GlobeNewsWire

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

COPENHAGEN, Denmark, October 3, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, continues to gather ...

8 months ago - GlobeNewsWire

Evaxion Biotech Partners With Merck To Expand Vaccine Development

Evaxion Biotech A/S EVAX inked an option and licensing deal with Merck & Co., Inc MRK for two preclinical vaccine candidates.

Other symbols: MRK
8 months ago - Benzinga

Evaxion significantly expands vaccine development collaboration with MSD

COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, tod...

8 months ago - GlobeNewsWire

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction

COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, lau...

9 months ago - GlobeNewsWire